Jerusalem, 20 October, 2026 (TPS-IL) — Epitomee Medical shares jumped approximately 15% on the Tel Aviv Stock Exchange, following progress in the Israeli company’s efforts to market its weight-loss capsule directly to consumers in the United States. The capsule works mechanically to promote fullness without medication. It received U.S. Food and Drug Administration clearance in September 2024.
Epitomee Medical has completed the setup of a direct-to-consumer sales platform in the U.S. and launched a digital platform where consumers seek access to the company’s weight-management capsule online.
The process includes a remote medical assessment by a licensed physician. Eligible patients can receive a prescription and have the product delivered to their homes through a licensed pharmacy. The company began paid and organic social-media marketing while evaluating and optimizing campaign performance.
Epitomee expects to begin direct U.S. sales by the end of 2026 but does not anticipate significant revenue from the new channel this year.
